LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 92

Search options

  1. Book: Tata Memorial Center Textbook of Oncology

    Badwe, Rajendra A / Gupta, Sudeep / Shrikhande, Shailesh V / Laskar, Siddhartha

    2024  

    Author's details Prof. Rajendra A Badwe completed his MBBS from the King Edward Memorial Hospital, Mumbai in 1978 followed by MS in General Surgery from the same institution. Subsequently he trained at Tata Memorial Hospital, Mumbai, Toronomon Hospital, Tokyo, and the Royal Marsden Hospital, London. He joined Tata Memorial Centre in the Department of Surgical Oncology (Breast Cancer Unit) as a faculty member in 1992 and has been the Director of TMC since 2008. He is an internationally renowned breast cancer surgeon and researcher with seminal contributions in several themes including use of peri-operative interventions to improve long-term outcomes. He has received numerous national and international awards, including the Padma Shri by the Government of India in 2013. Prof. Sudeep Gupta completed his MBBS, MD and DM (Medical Oncology) from the All India Institute of Medical Sciences, New Delhi in 2000 and has been a faculty member in the Department ofMedical Oncology, Tata Memorial Centre since 2001
    Keywords Cancer Screening ; Cancer Staging ; Lymphoid Malignancies ; Oncological Emergencies ; Intensive Care in Onclogy
    Language English
    Size 1061 p.
    Edition 2024
    Publisher Palgrave MacMillan UK
    Document type Book
    Note PDA Manuell_20
    Format 210 x 279
    ISBN 9789819933778 ; 9819933773
    Database PDA

    Kategorien

  2. Article: Tata Memorial Hospital: a Peerless Icon.

    Badwe, Rajendra A / Goel, Nishu Singh

    Indian journal of surgical oncology

    2022  Volume 13, Issue Suppl 1, Page(s) 27–29

    Abstract: Few institutes last long and fewer maintain their pre-eminent position throughout their life. They are called temples of their silo. Tata Memorial Hospital and Centre (TMC) is one such temple of healing. The contribution of TMC in patient care, education ...

    Abstract Few institutes last long and fewer maintain their pre-eminent position throughout their life. They are called temples of their silo. Tata Memorial Hospital and Centre (TMC) is one such temple of healing. The contribution of TMC in patient care, education and research is unique and reasons for its success are varied. It is probably the best  expression of Tata culture, Government's commitment, dedication and autonomy of people who ran it. A glimpse into the journey with its changing vision towards a pointed mission of conquest of cancer in India is captured in words.
    Language English
    Publishing date 2022-07-27
    Publishing country India
    Document type Journal Article
    ZDB-ID 2568289-1
    ISSN 0976-6952 ; 0975-7651
    ISSN (online) 0976-6952
    ISSN 0975-7651
    DOI 10.1007/s13193-022-01588-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Cancer Management in India during Covid-19.

    Pramesh, C S / Badwe, Rajendra A

    The New England journal of medicine

    2020  Volume 382, Issue 20, Page(s) e61

    MeSH term(s) Betacoronavirus ; COVID-19 ; Cancer Care Facilities/organization & administration ; Coronavirus Infections/complications ; Humans ; India ; Neoplasms/complications ; Neoplasms/therapy ; Pandemics ; Patient Care Management/methods ; Pneumonia, Viral/complications ; SARS-CoV-2 ; Triage
    Keywords covid19
    Language English
    Publishing date 2020-04-28
    Publishing country United States
    Document type Letter
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2011595
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Deciphering the mechanisms of action of progesterone in breast cancer.

    Chakravorty, Gaurav / Ahmad, Suhail / Godbole, Mukul S / Gupta, Sudeep / Badwe, Rajendra A / Dutt, Amit

    Oncotarget

    2023  Volume 14, Page(s) 660–667

    Abstract: A practice-changing, randomized, controlled clinical study established that preoperative hydroxyprogesterone administration improves disease-free and overall survival in patients with node-positive breast cancer. This research perspective summarizes ... ...

    Abstract A practice-changing, randomized, controlled clinical study established that preoperative hydroxyprogesterone administration improves disease-free and overall survival in patients with node-positive breast cancer. This research perspective summarizes evidences from our studies that preoperative hydroxyprogesterone administration may improve disease-free and overall survival in patients with node-positive breast cancer by modulating cellular stress response and negative regulation of inflammation. Non-coding RNAs, particularly
    MeSH term(s) Humans ; Female ; Breast Neoplasms/drug therapy ; Breast Neoplasms/genetics ; Breast Neoplasms/metabolism ; Progesterone/pharmacology ; Progesterone/therapeutic use ; Receptors, Progesterone/metabolism ; Signal Transduction ; Hydroxyprogesterones/therapeutic use
    Chemical Substances Progesterone (4G7DS2Q64Y) ; Receptors, Progesterone ; Hydroxyprogesterones
    Language English
    Publishing date 2023-07-01
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.28455
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Screening for breast cancer: Cost-effective solutions for low- & middle-income countries.

    Mishra, Gauravi A / Pimple, Sharmila A / Mittra, Indraneel / Badwe, Rajendra A

    The Indian journal of medical research

    2021  Volume 154, Issue 2, Page(s) 229–236

    Abstract: Low- and middle-income countries (LMICs) have limited financial resources and proportionately smaller portions allocated for health budget. With competing health priorities, treatment of the diagnosed cases and establishment of treatment facilities are ... ...

    Abstract Low- and middle-income countries (LMICs) have limited financial resources and proportionately smaller portions allocated for health budget. With competing health priorities, treatment of the diagnosed cases and establishment of treatment facilities are the main concerns in LMICs. Infectious diseases, reducing infant, child and maternal mortality may seem crucial as compared to early cancer detection. LMICs that are committed to providing comprehensive cancer care, will need to judiciously choose the screening tool depending on specifics of how the tool is expected to perform in the population and the cost-effectiveness with respect to the number of lives expected to be saved. Increasing awareness about breast health in general and common cancers and non communicable diseases (NCDs), in particular, may lead to symptomatic women approaching the healthcare facilities at an earlier stage. When the limited available resources are mobilized towards cancer screening, increasing awareness would lead to greater acceptability of the programme. The reach of the programme to achieve good population coverage, the establishment of the diagnostic referral linkages and the availability and accessibility of treatment facilities, will all decide the outcome of the screening programme.
    MeSH term(s) Breast Neoplasms/diagnosis ; Breast Neoplasms/epidemiology ; Cost-Benefit Analysis ; Developing Countries ; Early Detection of Cancer ; Female ; Humans ; Mass Screening
    Language English
    Publishing date 2021-12-02
    Publishing country India
    Document type Journal Article ; Review
    ZDB-ID 390883-5
    ISSN 0971-5916 ; 0019-5340
    ISSN 0971-5916 ; 0019-5340
    DOI 10.4103/ijmr.IJMR_2635_20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Clinical Benefit of Circulating Tumor DNA Analysis in Early-Stage Breast Cancer.

    Chitkara, Garvit / Hawaldar, Rohini / Badwe, Rajendra A

    JAMA oncology

    2019  Volume 6, Issue 3, Page(s) 439

    MeSH term(s) Biomarkers, Tumor ; Breast Neoplasms ; Circulating Tumor DNA ; Humans ; Neoplasm Recurrence, Local
    Chemical Substances Biomarkers, Tumor ; Circulating Tumor DNA
    Language English
    Publishing date 2019-12-17
    Publishing country United States
    Document type Letter ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2019.5677
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Intent of surgery of the primary tumor in metastatic breast cancer remains palliative.

    Nair, Nita S / Parmar, Vani / Badwe, Rajendra A

    The breast journal

    2019  Volume 25, Issue 2, Page(s) 353

    MeSH term(s) Breast Neoplasms ; Databases, Factual ; Humans ; Palliative Care
    Language English
    Publishing date 2019-02-13
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1289960-4
    ISSN 1524-4741 ; 1075-122X
    ISSN (online) 1524-4741
    ISSN 1075-122X
    DOI 10.1111/tbj.13224
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma.

    Narwadkar, Yoga S / Parghane, Rahul V / Sahu, Sudeep / Lad, Sangita / Deep, Kamal / Wanage, Gaurav / Suralkar, Tejal / Banerjee, Sharmila / Gupta, Sudeep / Basu, Sandip / Badwe, Rajendra A

    Clinical nuclear medicine

    2024  Volume 49, Issue 4, Page(s) e149–e155

    Abstract: Objective: The aim of this study was to assess the biodistribution and dosimetry of 177 Lu-DOTA-trastuzumab in patients with HER2-positive breast carcinoma using whole-body (WB) planar imaging at multiple time points.: Patients and methods: This ... ...

    Abstract Objective: The aim of this study was to assess the biodistribution and dosimetry of 177 Lu-DOTA-trastuzumab in patients with HER2-positive breast carcinoma using whole-body (WB) planar imaging at multiple time points.
    Patients and methods: This study was a prospective evaluation of HER2-positive metastatic/locally advanced breast carcinoma patients who underwent gamma camera imaging for dosimetry and biodistribution studies by using 177 Lu-DOTA-trastuzumab. The standard diagnostic dosimetry protocol was followed, which included cold trastuzumab injection followed by in-house produced 177 Lu-DOTA-trastuzumab. Serial WB planar images (anterior and posterior) were obtained on gamma camera after the infusion of 177 Lu-DOTA-trastuzumab at multiple time points. Whole-body and organ regions of interest were drawn, and the numbers of disintegrations were obtained. The mean absorbed doses for the liver, spleen, kidneys, heart, red marrow, and tumor were obtained from OLINDA EXM v2.1.1 and ORIGIN software.
    Results: The study included a cohort of 21 female breast carcinoma patients. Tracer activity ( 177 Lu-DOTA-trastuzumab) was noted in the physiological organs such as the liver, spleen, kidneys, heart, as well as in the tumors. On visual analysis of 177 Lu-DOTA-trastuzumab biodistribution, the liver activity showed gradual clearance over time, and although spleen was comparatively faintly visualized than liver and similarly, kidneys were faintly visualized suggestive of the alternate route of tracer excretion. The maximum number of patients (n = 12) showed 2 components of clearance, namely, fast and slow. The average effective half-life of all the patients (including single and 2 components of clearance) was 106.25 ± 22.14 hours (84.11-128.39 hours). The mean absorbed dose for the liver, spleen, kidneys, heart, whole body, and red marrow was 1.0702 ± 0.731, 1.4114 ± 0.462, 1.4232 ± 0.364, 1.4719 ± 0.602, 0.2412 ± 0.0295, and 0.1485 ± 0.0213 mGy/MBq, respectively, by OLINDA EXM and 0.5741 ± 0.333, 0.8096 ± 0.224, 0.7943 ± 0.235, 1.8971 ± 0.713, and 0.09619 ± 0.0144 for liver, spleen, kidneys, heart and whole body respectively by ORIGIN. The absorbed radiation dose for tumor was 1.94E+2 by OLINDA EXM software and 1.78E+2 by ORIGIN software. In this study, during and after infusion of 177 Lu-DOTA-trastuzumab, no major adverse effects were noted in any patient except 1 patient who had grade 1 nausea and managed conservatively by antiemetic drug.
    Conclusions: The results of our study demonstrated expected and favorable biodistribution and dosimetry with 177 Lu-DOTA-trastuzumab in HER2-positive breast carcinoma patients. We noticed the mean absorbed dose to the normal organs within the limits of maximum tolerable dose, and also tumor dose was higher than the normal liver dose. Therefore, we conclude that 177 Lu-DOTA-trastuzumab radioimmunotherapy is feasible and a safe treatment option for treating HER2-positive breast carcinoma patients.
    MeSH term(s) Humans ; Female ; Tissue Distribution ; Trastuzumab/therapeutic use ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/therapy ; Heterocyclic Compounds, 1-Ring ; Lutetium ; Radioisotopes
    Chemical Substances 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid (1HTE449DGZ) ; Trastuzumab (P188ANX8CK) ; Lutetium-177 (BRH40Y9V1Q) ; Heterocyclic Compounds, 1-Ring ; Lutetium (5H0DOZ21UJ) ; Radioisotopes
    Language English
    Publishing date 2024-02-01
    Publishing country United States
    Document type Journal Article
    ZDB-ID 197628-x
    ISSN 1536-0229 ; 0363-9762
    ISSN (online) 1536-0229
    ISSN 0363-9762
    DOI 10.1097/RLU.0000000000005067
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Geographical & seasonal variation in COVID-19 related mortality.

    Badwe, Rajendra A / Dikshit, Rajesh / Chaturvedi, Pankaj / Gupta, Sudeep

    The Indian journal of medical research

    2020  Volume 152, Issue 1 & 2, Page(s) 6–8

    MeSH term(s) Betacoronavirus/pathogenicity ; COVID-19 ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Female ; Humans ; Male ; Pandemics ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Seasons
    Keywords covid19
    Language English
    Publishing date 2020-08-10
    Publishing country India
    Document type Journal Article
    ZDB-ID 390883-5
    ISSN 0971-5916 ; 0019-5340
    ISSN 0971-5916 ; 0019-5340
    DOI 10.4103/ijmr.IJMR_2043_20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top